Back to top

Analyst Blog

Zacks Equity Research

Haemonetics: Medical Center of Plano Picks BloodTrack

BAX HAE NXTM BVX

Trades from $3

Haemonetics Corporation (HAE - Free Report) , a global provider of healthcare technology and products, recently announced the installation of its BloodTrack Emerge software at The Medical Center of Plano. The software has been deployed for blood management at the time of emergency.

Several healthcare organizations in the U.S. use the BloodTrack solution for blood transfusion to trauma patients. The Medical Center of Plano will deploy BloodTrack within its Emergency Department (ED) to provide authorized caregivers with "just-in-time blood management" in the trauma room.

We note that BloodTrack is a modular blood management and bedside transfusion technology that combines software with hardware components to act as an extension of a patient’s blood bank transfusion management system. BloodTrack provides the necessary control, visibility and traceability to safely store and properly dispense blood products in clinical areas. The tracker also ensures that the right group of blood is transfused to the required patient at the bedside.

According to the Medical Center of Plano, immediate access to blood products can make a life-saving difference. The physicians think that Haemonetics’ product is the most advanced option available to treat trauma patients. Notably, physicians treating 30-40 trauma cases per month can begin the resuscitation process for critically injured patients. They can obtain blood products directly from the BloodTrack Emerge system in the trauma room.

As per a BCC Research report, the global market for blood products is currently worth $23.5 billion and is expected to reach $28.8 billion in 2017, at a CAGR of 4.1%.

In the recently concluded quarterly report, Haemonetics reported growth acceleration in BloodTrack and SafeTrace Tx products under its Hospital business segment. This marks the company’s progress in targeting hospitals with better blood supply chain, enhanced patient safety, advanced quality of medical care and lower costs.

Zacks Rank & Other Key Picks

Haemonetics currently carries a Zacks Rank #2 (Buy). Other favorably ranked medical stocks are NxStage Medical Inc. (NXTM - Free Report) , Baxter International Inc. (BAX - Free Report) and Bovie Medical Corporation (BVX - Free Report) . NxStage Medical and Baxter International sport a Zacks Rank #1 (Strong Buy) while Bovie Medical carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

NxStage Medical surged 30.7% over the last one year compared to the S&P 500’s 5.4% over the same period. The company has a four-quarter average positive earnings surprise of 50.00%.

Baxter International rallied 23.6% over one year, much higher than the S&P 500’s 5.4%. It has a trailing four-quarter average positive earnings surprise of 27%.

Bovie Medical recorded a 130.0% gain in the past one year, way better than the S&P 500’s 5.4%. The company has a trailing four-quarter positive average earnings surprise of 28.7%.

The Best Place to Start Your Stock Search

Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BAXTER INTL (BAX) - free report >>

HAEMONETICS CP (HAE) - free report >>

NXSTAGE MEDICAL (NXTM) - free report >>

BOVIE MEDICAL (BVX) - free report >>